Valuation: Alumis Inc.

Market Cap 3.37B 2.95B 2.72B 2.55B 4.78B 318B 4.87B 32.7B 12.65B 157B 12.64B 12.36B 544B P/E 2026 *
-9.19x
P/E 2027 * -9.66x
Enterprise Value 2.83B 2.48B 2.29B 2.14B 4.02B 267B 4.1B 27.5B 10.64B 132B 10.63B 10.4B 458B EV / Sales 2026 *
362x
EV / Sales 2027 * 126x
Free-Float
96.2%
Yield 2026 *
-
Yield 2027 * -
1 day+5.47%
1 week+12.77%
Current month+22.22%
1 month+18.23%
3 months+0.30%
6 months+140.66%
Current year+170.49%
1 week 22.96
Extreme 22.96
26.5
1 month 18.36
Extreme 18.36
26.5
Current year 7.85
Extreme 7.85
30.6
1 year 2.92
Extreme 2.92
30.6
3 years 2.76
Extreme 2.7601
30.6
5 years 2.76
Extreme 2.7601
30.6
10 years 2.76
Extreme 2.7601
30.6
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 61 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 62 2021-04-30
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Date Insider Type Main position Quantity % Market Cap.
05-21Fiscal year

Chief Technology Officer

53,704 0.0468%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
Change 5-day change 1-year change 3-year change Capi.($)
+5.47%+12.77%+700.00% - 3.37B
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.65%+5.58%+108.03%+128.88% 22.97B
Weighted average by Cap. +0.34%+5.24%+58.05%+120.17%

Financials

2026 *2027 *
Net sales 7.82M 6.85M 6.32M 5.91M 11.09M 737M 11.32M 75.92M 29.38M 364M 29.35M 28.71M 1.26B 23.83M 20.9M 19.26M 18.03M 33.82M 2.25B 34.52M 232M 89.59M 1.11B 89.5M 87.55M 3.85B
Net income -375M -329M -303M -284M -532M -35.36B -543M -3.64B -1.41B -17.48B -1.41B -1.38B -60.6B -397M -348M -321M -300M -563M -37.43B -575M -3.85B -1.49B -18.5B -1.49B -1.46B -64.14B
Net Debt -534M -469M -432M -404M -758M -50.42B -774M -5.19B -2.01B -24.92B -2.01B -1.96B -86.4B -371M -325M -300M -281M -526M -34.97B -537M -3.6B -1.39B -17.29B -1.39B -1.36B -59.94B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
26-06-26 US$26.40 +5.47% 6,164,556
26-06-25 US$25.03 +0.72% 1,117,307
26-06-24 US$24.85 +1.39% 956,385
26-06-23 US$24.51 -0.37% 1,185,461
26-06-22 US$24.60 +5.08% 1,435,836
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26.40USD
Average target price
40.10USD
Spread / Average Target
+51.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock